Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
ACUVUE THERAVISION WITH KETOTIFEN vs BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine